Search in:

Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 12

Submit an article Journal homepage

294

Views

CrossRef citations to date

Altmetric

Reviews

Biologics in asthma: difficulties and drawbacks

Jean Bousquet Hôpital Arnaud de Villeneuve, Service des Maladies Respiratoires, 34295- Montpellier, Cedex 05, France +33 467 33 61 05; +33 467 04 27 08; [email protected]; INSERM UMR 780, Villejuif, France; Member of GALEN (Global Allergy and Asthma European Network), supported by the Sixth EU Framework programme for research, contract number FOOD-CT-2004-506378

Raphael Chiron Hôpital Arnaud de Villeneuve, Service des Maladies Respiratoires, 34295- Montpellier, Cedex 05, France +33 467 33 61 05; +33 467 04 27 08; [email protected]; Member of GALEN (Global Allergy and Asthma European Network), supported by the Sixth EU Framework programme for research, contract number FOOD-CT-2004-506378

Marc Humbert Université Paris-Sud 11, Hôpital Antoine Béclère, Service de Pneumologie, 157, rue de la Porte de Trivaux, 92140 Clamart, France

Pages 1921-1928 | Published online: 06 Nov 2008

Cite this article
https://doi.org/10.1517/14712590802496928

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Lonberg N. Human monoclonal antibodies from transgenic mice. Handb Exp Pharmacol 2008;181:69-97
PubMedGoogle Scholar
Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol 2008;181:3-18
PubMedGoogle Scholar
MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004;114(6):1472-4
PubMed Web of Science ®Google Scholar
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 2004;114(3):527-30
PubMed Web of Science ®Google Scholar
Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115(3):459-65
PubMed Web of Science ®Google Scholar
Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93
PubMed Web of Science ®Google Scholar
Fahy JV. Anti-IgE. lessons learned from effects on airway inflammation and asthma exacerbation. J Allergy Clin Immunol 2006;117(6):1230-2
PubMed Web of Science ®Google Scholar
Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35(4):408-16
PubMed Web of Science ®Google Scholar
Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8
PubMed Web of Science ®Google Scholar
Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101(7):1483-92
PubMed Web of Science ®Google Scholar
Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
PubMed Web of Science ®Google Scholar
Kon OM, Sihra BS, Loh LC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001;18(1):45-52
PubMed Web of Science ®Google Scholar
Kon OM, Sihra BS, Compton CH, et al. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352(9134):1109-13
PubMed Web of Science ®Google Scholar
Simon D, Braathen LR, Simon HU. Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005;72(6):287-92
PubMed Web of Science ®Google Scholar
Pauwels RA, Brusselle GJ, Kips JC. Cytokine manipulation in animal models of asthma. Am J Respir Crit Care Med 1997;156(4 Pt 2):S78-81
PubMed Web of Science ®Google Scholar
Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-8
PubMed Web of Science ®Google Scholar
Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-71
PubMed Web of Science ®Google Scholar
Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007;119(6):1303-10; quiz 1311-2
PubMed Web of Science ®Google Scholar
O'Byrne PM. The demise of anti IL-5 for asthma, or not. Am J Respir Crit Care Med 2007;176(11):1059-60
PubMed Web of Science ®Google Scholar
Van Rensen EL, Stirling RG, Scheerens J, et al. Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax 2001;56(12):935-40
PubMed Web of Science ®Google Scholar
Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112(7):1029-36
PubMed Web of Science ®Google Scholar
Plotz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-9
PubMed Web of Science ®Google Scholar
Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118(5):1133-41
PubMed Web of Science ®Google Scholar
Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107(6):963-70
PubMed Web of Science ®Google Scholar
Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160(6):1816-23
PubMed Web of Science ®Google Scholar
Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31
PubMed Web of Science ®Google Scholar
Heffler E, Berry M, Pavord ID. Tumor necrosis factor-α: a promising therapeutic target for asthma? BioDrugs 2007;21(6):345-9
PubMed Web of Science ®Google Scholar
Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N Engl J Med 2006;354(7):697-708
PubMed Web of Science ®Google Scholar
Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12):1012-8
PubMed Web of Science ®Google Scholar
Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121(2):288-96; quiz 297-8
PubMed Web of Science ®Google Scholar
Schaafsma D, Gosens R, Zaagsma J, et al. Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol 2008;585(2-3):398-406
PubMed Web of Science ®Google Scholar
Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61(8):912-20
PubMed Web of Science ®Google Scholar
Georgitis JW, Browning MC, Steiner D, Lorentz WB. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. Ann Allergy 1991;66(4):343-7
PubMedGoogle Scholar
Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72(4):250-6
PubMed Web of Science ®Google Scholar
Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists. Curr Opin Allergy Clin Immunol 2007;7(5):393-403
PubMed Web of Science ®Google Scholar
Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007;96(1):128-30
PubMedGoogle Scholar
Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25(1):40-6
PubMed Web of Science ®Google Scholar
Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65(6):753-9
PubMed Web of Science ®Google Scholar
Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48(1):35-45
PubMed Web of Science ®Google Scholar
Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol 2001;137(7):893-9
PubMed Web of Science ®Google Scholar
Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitis-like reaction to subcutaneous etanercept injection. Arch Dermatol 2006;142(2):218-20
PubMed Web of Science ®Google Scholar
Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-α blocking agents with positive skin tests. Allergy 2008;63(1):138-9
PubMed Web of Science ®Google Scholar
Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10(4):333-8
PubMed Web of Science ®Google Scholar
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12(5):601-9
PubMed Web of Science ®Google Scholar
Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park) 2006;20(11):1373-82; discussion 1382, 1392-4, 1397
PubMed Web of Science ®Google Scholar
O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25(24):3644-8
PubMed Web of Science ®Google Scholar
Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 2008;358(11):1109-17
PubMed Web of Science ®Google Scholar
Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007;120(6):1378-81
PubMed Web of Science ®Google Scholar
Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120(6):1373-7
PubMed Web of Science ®Google Scholar
Sampson HA, Munoz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005;115(3):584-91
PubMed Web of Science ®Google Scholar
Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease–seven years on. Aliment Pharmacol Ther 2006;23(4):451-63
PubMed Web of Science ®Google Scholar
Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007;120(4):972-3
PubMed Web of Science ®Google Scholar
Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37(2):197-207
PubMed Web of Science ®Google Scholar
Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006;54(12):3782-9
PubMed Web of Science ®Google Scholar
Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007;46(12):1828-34
PubMed Web of Science ®Google Scholar
Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007;25(6):675-80
PubMed Web of Science ®Google Scholar
Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13(16):2328-32
PubMed Web of Science ®Google Scholar
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
PubMed Web of Science ®Google Scholar
Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-53
PubMed Web of Science ®Google Scholar
Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22(9):1765-76
PubMed Web of Science ®Google Scholar
Krishnan JA, Gould M. Omalizumab for severe allergic asthma: dollars and sense. J Allergy Clin Immunol 2007;120(5):1015-7
PubMed Web of Science ®Google Scholar
Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120(5):1146-52
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Biologics in asthma: difficulties and drawbacks

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Biologics in asthma: difficulties and drawbacks

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date